102 related articles for article (PubMed ID: 36000370)
1. [An exploratory clinical study of the efficacy and safety of tumor-infiltrating lymphocytes in the treatment of metastatic osteosarcoma].
Wang CR; Kang M; Xu J; Lyu Y; Jiang YF; Sun MX; Zuo DQ; Shen JK; Ma XJ; Sun W; Hua YQ; Cai Z
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2421-2427. PubMed ID: 36000370
[No Abstract] [Full Text] [Related]
2. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
3. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.
Rosenberg SA; Yannelli JR; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
J Natl Cancer Inst; 1994 Aug; 86(15):1159-66. PubMed ID: 8028037
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.
Quattrocchi KB; Miller CH; Cush S; Bernard SA; Dull ST; Smith M; Gudeman S; Varia MA
J Neurooncol; 1999; 45(2):141-57. PubMed ID: 10778730
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
6. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
Deniger DC; Kwong ML; Pasetto A; Dudley ME; Wunderlich JR; Langhan MM; Lee CR; Rosenberg SA
Clin Cancer Res; 2017 Jan; 23(2):351-362. PubMed ID: 28093487
[TBL] [Abstract][Full Text] [Related]
7. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes.
Ligon JA; Choi W; Cojocaru G; Fu W; Hsiue EH; Oke TF; Siegel N; Fong MH; Ladle B; Pratilas CA; Morris CD; Levin A; Rhee DS; Meyer CF; Tam AJ; Blosser R; Thompson ED; Suru A; McConkey D; Housseau F; Anders R; Pardoll DM; Llosa N
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021032
[TBL] [Abstract][Full Text] [Related]
8. Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Pillai M; Jiang Y; Lorigan PC; Thistlethwaite FC; Thomas M; Kirillova N; Bridgeman JS; Kueberuwa G; Biswas S; Velazquez P; Chonzi D; Guest RD; Roberts ZJ; Hawkins RE
Am J Cancer Res; 2022; 12(8):3967-3984. PubMed ID: 36119832
[TBL] [Abstract][Full Text] [Related]
9. Autologous Tumor-Infiltrating Lymphocyte Mono-Therapy Can Rapidly Shrank Tumor in Asian Patient with Stage III/IV Cervical Cancer: Two Cases Report.
Li F; Wang Y; Yan J; Wu H; Du X; Feng W; Zhang X; Xue Y; Wang H; Liu W
Int J Womens Health; 2024; 16():31-39. PubMed ID: 38222312
[TBL] [Abstract][Full Text] [Related]
10. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
Zhang YX; Wang XY; Liu JB; Zhang SQ; Chen YR
Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(14):973-6. PubMed ID: 18756970
[TBL] [Abstract][Full Text] [Related]
11. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Heemskerk B; Liu K; Dudley ME; Johnson LA; Kaiser A; Downey S; Zheng Z; Shelton TE; Matsuda K; Robbins PF; Morgan RA; Rosenberg SA
Hum Gene Ther; 2008 May; 19(5):496-510. PubMed ID: 18444786
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.
Wen XZ; Pan QZ; Xu BS; Xiao W; Weng DS; Zhao JJ; Xu HR; Huang Z; Niu XH; Zhang X
Cancer Chemother Pharmacol; 2022 Feb; 89(2):209-215. PubMed ID: 35022817
[TBL] [Abstract][Full Text] [Related]
14. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo isolation, expansion and bioengineering of CCR7+CD95-/or CD62L+CD45RA+ tumor infiltrating lymphocytes from acute myeloid leukemia patients' bone marrow.
Cao H; Kim DH; Howard A; Moz H; Wasnik S; Baylink DJ; Chen CS; Reeves ME; Mirshahidi S; Xiao J; Francis O; Marcucci G; Xu Y
Neoplasia; 2021 Dec; 23(12):1252-1260. PubMed ID: 34775232
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
17. The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Uryvaev A; Passhak M; Hershkovits D; Sabo E; Bar-Sela G
Med Oncol; 2018 Jan; 35(3):25. PubMed ID: 29388007
[TBL] [Abstract][Full Text] [Related]
18. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study.
Gaspar N; Venkatramani R; Hecker-Nolting S; Melcon SG; Locatelli F; Bautista F; Longhi A; Lervat C; Entz-Werle N; Casanova M; Aerts I; Strauss SJ; Thebaud E; Morland B; Nieto AC; Marec-Berard P; Gambart M; Rossig C; Okpara CE; He C; Dutta L; Campbell-Hewson Q
Lancet Oncol; 2021 Sep; 22(9):1312-1321. PubMed ID: 34416158
[TBL] [Abstract][Full Text] [Related]
20. In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice.
Wong RA; Alexander RB; Puri RK; Rosenberg SA
J Immunother (1991); 1991 Apr; 10(2):120-30. PubMed ID: 2043592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
